Drug Trial Radar · NCT04574791
Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
240
Actual
Start
Sep 3, 2020
Primary completion
Sep 30, 2021
Study completion Sep 30, 2021
Sponsor
- Lead sponsor
- Rothman Institute OrthopaedicsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a prospective, cluster-randomized, two-arm, comparative study aimed at determining whether addition of tizanidine ( an oral muscle relaxant) to a multimodal pain regimen following primary TKA reduces opioid consumption.
Conditions
- Pain, Postoperative
Interventions
TiZANidine 2 MG Oral CapsuleDrug
Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- opioid consumption (MME) postoperativelyTime frame: the first 14-days postoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.